Experimental drug for rare inflammatory disease shows early promise but trial cut short
NCT ID NCT04918147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe or effective. Participants received either elotuzumab plus prednisone or a placebo plus prednisone, and the main goal was to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elotuzumab (a monoclonal antibody)
What this could lead to
If it works, this could point toward a new treatment option for IgG4-related disease, reducing reliance on steroids.
What could go wrong
This trial was terminated early with only 8 participants enrolled, so results are very limited. It is too early to know if elotuzumab is safe or effective for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Healthcare
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic: Pulmonary and Critical Care Medicine
Rochester, Minnesota, 55905, United States